Type of the study
|
Study time
|
Sample size
|
Rate of anti-TB resistance
|
---|
Primary resistance
|
Secondary resistance
|
Overall resistance (primary plus secondary resistance)
|
---|
Any-resistance (%)
|
MDR-TB (%)
|
Any- resistance (%)
|
MDR-TB (%)
|
Any- resistance (%)
|
MDR-TB (%)
|
---|
Community-based
|
Institution-based
|
---|
Current study
| |
2014
|
33073a
|
15.3
|
2.4
|
48.8
|
14.3
|
21.7
|
4.7
|
|
Demissie M et al. [34]
|
1994
|
167b
|
15.6
|
0.6
| | | | |
|
Bruchfeld et. al [22]
|
1996–1997
|
509
|
14.6
|
0.9
|
11.1
|
0
|
15.7
|
1.7
|
|
Abate et al. [35]
|
1998
|
30c
| | | | |
50
|
12
|
|
Demissie et al. [40]
|
1998
| |
12.9
|
0.6
| | | | |
|
Gebeyehu M et al. [23]
|
2001
|
203
|
18.2
|
0
|
31.6
|
0
|
19.5
|
0
|
|
First National Drug resistance survey [7]
|
2003–2005
|
804
| |
1.6
| |
11.5
| | |
|
Desta K et al. [36]
|
2004–2005
|
297b
|
27.4
|
0
| | | | |
|
Abate D et al. [13]
|
2004–2008
|
376c
| | |
72.9
|
46.3
| | |
|
Asmamaw et al. [25]
|
2004–2005
|
173b
|
21.4
|
0.6
| | | | |
|
Agonafir M et al. [9]
|
2005–2006
|
114c
|
25
|
2.3
|
85.7
|
63.5
|
60.8
|
38.3
|
|
Tessema B et al. [10]
|
2009
|
260
|
10.7
|
3.7
|
39.1
|
10.9
|
15.8
|
5.0
|
|
Abebe G et al. [11]
|
2010–2011
|
136b
|
18.4
|
1.5
| | | | |
|
Esmael A et al. [37]
|
2010–2011
|
230
|
23.6
|
1.8
|
58.5
|
18.5
|
33.5
|
6.5
|
|
Yimer et al. [26]
|
2012
|
112b
|
30.1
|
1.0
| | | | |
|
Seyoum et al. [8]
|
2011–2013
|
408b
|
23
|
1.1
| | | | |
|
Nigus et al. [12]
|
2012–2013
|
606b
| | | |
15.3
| | |
|
Second National Drug resistance survey (7)
|
2014
|
1651
| |
2.3
| |
17.8
| | |
|
Mulisa G et al. [38]
|
2015
|
439c
| | | |
33.2 %
| | |
-
a Of the study population, 106 TB cases were diagnosed
-
b Only new cases
-
c Previously treated and now presumptive for MDR-TB